Global Antibody Therapeutics Market Analysis Report 2022-2027 - Key Manufacturers are Striving to Reduce In-house Operations to Leverage the Capabilities of CDMOs
26 sept. 2022 04h38 HE
|
Research and Markets
Dublin, Sept. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Antibody Therapeutics Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This research service offers an...
Global ROR1-Targeted Therapy Market Analysis Report 2022: Scientific Rationale for ROR1-targeted Therapies Based on Target Characteristics
05 août 2022 07h38 HE
|
Research and Markets
Dublin, Aug. 05, 2022 (GLOBE NEWSWIRE) -- The "ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis" report...
Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
30 juin 2022 14h24 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; June 30, 2022 – Genmab A/S (Nasdaq: GMAB) today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug...
Global $5.13 Billion Bi-Specific MAbS Market Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F
21 juin 2022 07h08 HE
|
Research and Markets
Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The market is expected to reach $11.64...
Bispecific Antibody Market Size [2022-2029] | Global Industry Growth, Share, Demand Insights, Trends, Key Players, Geographical Segmentation, Gross Margin and Revenue, Key Findings and Forecast Research | Market Reports World
16 juin 2022 09h51 HE
|
Market Reports World
Pune, June 16, 2022 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market research report [2022-2029] has been prepared by experienced and knowledgeable market analysts and researchers. It is a...
NovalGen announces compelling data from the Phase 1/2 Study of NVG-111 at the ASCO Annual Meeting
26 mai 2022 18h00 HE
|
NovalGen Ltd.
- First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory CLL and MCL - Early data demonstrates promising efficacy with a predictable and...
Insights on the Bispecific Antibody Global Market - Approved Drug Sales Forecast Till 2028
23 mai 2022 06h43 HE
|
Research and Markets
Dublin, May 23, 2022 (GLOBE NEWSWIRE) -- The "Global Bispecific Antibody Market Opportunity, Drug Sales, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's...
Global Next-Generation Antibody Market Report 2022: A US$ 12,050.13 Million Market by 2028, Growing at a CAGR of 11.9% During 2021-2028
21 avr. 2022 04h08 HE
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Next-Generation Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutic Area and Technology" report has been added to...
Global TRAIL Receptor 2 Agonists Pipeline Landscape Report 2021
17 déc. 2021 06h53 HE
|
Research and Markets
Dublin, Dec. 17, 2021 (GLOBE NEWSWIRE) -- The "TRAIL Receptor 2 Agonists - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides...
$4 Billion Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Market Outlook, 2028
08 déc. 2021 07h18 HE
|
Research and Markets
Dublin, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The "Rybrevant Bispecific Antibody Patent, Sales & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. Market...